G M1 -gangliosidosis and Morquio B are rare lysosomal storage diseases associated with a neurodegenerative disorder or dwarˆsm and skeletal abnormalities, respectively. These diseases are caused by deˆciencies in the lysosomal enzyme human b-D-galactosidase (h-b-GAL), which lead to accumulations of the h-b-GAL substrates, G M1 ganglioside and keratan sulfate due to mutations in the h-b-GAL gene. H-b-GAL is an exoglycosidase that catalyzes the hydrolysis of terminal b-linked galactose residues. Here, we present the crystal structures of h-b-GAL in complex with its catalytic product galactose or with its inhibitor 1-deoxygalactonojirimycin. H-b-GAL showed a novel homodimer structure; each monomer was comprised of a catalytic TIM barrel domain followed by b-domain 1 and b-domain 2. The long loop region connecting the TIM barrel domain with b-domain 1 was responsible for the dimerization. To gain structural insight into the molecular defects of h-b-GAL in the above diseases, the disease-causing mutations were mapped onto the three-dimensional structure. Finally, the possible causes of the diseases are discussed. 
Substrates for b-GAL, ganglioside GM1 and keratin sulphate, are shown. Galactose at the edge is colored grey and the cleavage site is indicated by an arrow. Ceramide is omitted for clarity.
Fig. 2. Overall Architecture of Human b-GAL
A. Domain organization of b-GAL. Human b-GAL cDNA encodes 677 amino acid residues. The enzyme is synthesized as an 88-kDa precursor and is processed to the 64-kDa mature enzyme by proteolytic cleavage. Mature form, puriˆed protein in this study and ordered region in the crystal are also shown. B. Monomer structure of human b-GAL in the b-GAL/galactose complex. b-GAL consists of three domains. The color scheme is the same as that in Fig. 2A . The bound galactose is shown as CPK model. C. Dimeric structure of human b-GAL. 
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